Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Constitutive NF-κB signaling is crucial for survival in multiple myeloma (MM) and other cancers.
• Current NF-κB-targeting therapies lack specificity, leading to toxicity in normal cells.

Purpose of the Study:

• To identify a specific therapeutic target within the NF-κB pathway for MM treatment.
• To develop a novel agent that selectively eliminates cancer cells while sparing normal cells.

Main Methods:

• Utilized a drug-discovery strategy to identify inhibitors of the GADD45β/MKK7 interaction.
• Developed a D-tripeptide, named DTP3, designed to disrupt this complex.
• Evaluated the efficacy and specificity of DTP3 in vitro and in vivo models of MM.

Main Results:

• DTP3 effectively disrupts the GADD45β/MKK7 complex, leading to MM cell death.
• DTP3 demonstrates over 100-fold greater cancer cell specificity compared to the clinical standard, bortezomib, in vitro.
• DTP3 treatment eradicated myeloma xenografts in mice without apparent side effects at effective doses.

Conclusions:

• Targeting the NF-κB pathway selectively is achievable and offers significant therapeutic potential.
• DTP3 represents a novel, highly specific therapeutic agent for multiple myeloma with a favorable safety profile.